Cargando…

Complete metastasectomy after high-dose interleukin-2 (HD IL-2) therapy for melanoma

Detalles Bibliográficos
Autores principales:	Chu, Melinda, Hsueh, Eddy, Richart, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645297/ http://dx.doi.org/10.1186/2051-1426-3-S2-P130

Ejemplares similares

High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases
por: Chu, Melinda B., et al.
Publicado: (2013)

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
por: Kaufman, Howard L, et al.
Publicado: (2014)

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
por: Clark, Joseph I, et al.
Publicado: (2015)

The role of surgery following incomplete response to high-dose IL-2 (HD IL-2)
por: Hughes, Tasha, et al.
Publicado: (2013)

Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease
por: Hughes, Tasha, et al.
Publicado: (2013)

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
por: Wong, Michael KK, et al.
Publicado: (2015)

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
por: Buchbinder, Elizabeth I., et al.
Publicado: (2019)

A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01)
por: Clark, Joseph, et al.
Publicado: (2014)

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02)
por: Patel, Sapna, et al.
Publicado: (2014)

High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
por: Chow, Shien, et al.
Publicado: (2014)

Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
por: Andersen, Rikke, et al.
Publicado: (2014)

Associations of Fc gamma receptor (FcgR2a, FcgR3a and FcgR2c) genotype with outcome in metastatic renal cell carcinoma (mRCC) patients receiving high dose interleukin 2 (HD-IL2)
por: Erbe, Amy K, et al.
Publicado: (2015)

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates
por: Wong, Michael K, et al.
Publicado: (2013)

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
por: Davar, Diwakar, et al.
Publicado: (2017)

Impact of annual hospital volume of high dose interleukin-2 infusions on in-patient mortality in patients with melanoma and renal cell carcinoma
por: Mehta, Kathan, et al.
Publicado: (2015)

Development of an adoptive cell therapy protocol with tumor-infiltrating lymphocytes and intermediate-dose interleukin-2 therapy
por: Nguyen, Linh T, et al.
Publicado: (2013)

Feasibility of dc vaccine combined with low dose endoxan and high dose il-2 treatment associated with taurolidine for advanced, multi-resistant melanoma patients.
por: Moviglia, Gustavo A, et al.
Publicado: (2015)

High-dose IL-2 in metastatic melanoma: better survival in patients who also received patient-specific autologous tumor cell vaccine
por: Dillman, Robert O, et al.
Publicado: (2013)

Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex
por: Zloza, Andrew, et al.
Publicado: (2013)

IL-2, IL-15 and IL-21 expand T cells for targeted adoptive therapy
por: Liu, Zhenjiang, et al.
Publicado: (2015)

Stable disease, diagnosis and dose are prognostic factors for survival after interleukin-2 immunotherapy
por: Kwan, Nathan H, et al.
Publicado: (2015)

Electrotransfer of IL-15/IL-15Rα complex for the treatment of established melanoma
por: Shirley, Shawna, et al.
Publicado: (2015)

Formation of woody biomass is regulated by class III HD Zip genes
por: Robischon, Marcel
Publicado: (2011)

High Th17:Treg ratio may predict complete response to HDIL-2 in the setting of melanoma
por: Diller, Maggie L, et al.
Publicado: (2015)

Activity of dose-dense outpatient intravenous Interleukin-2 preceded by famotidine in metastatic clear cell cancer of the kidney
por: Quan, Walter, et al.
Publicado: (2013)

Interleukin-15 (IL-15) and IL-15 receptor alpha fusion protein enhances antitumor activity of myxoma virus
por: Tosic, Vesna, et al.
Publicado: (2013)

IL-2 analogues: novel agents circumventing the expansion of T regulatory cells while promoting NK cell activation during IL-2 therapy
por: Sim, Geok Choo, et al.
Publicado: (2013)

Interleukin (IL)- 6 inhibition - Follow-up data of the German AID-registry(1)
por: Bielak, M, et al.
Publicado: (2015)

Clinical outcomes of Interleukin-2 therapy in advanced cancer: meta-analysis of over 62 trials
por: Coventry, Brendon J, et al.
Publicado: (2013)

Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma
por: Chandar, Ashwin, et al.
Publicado: (2015)

Improving adoptive T cell therapy with adenoviruse armed with TNF-α and IL-2
por: Havunen, Riikka, et al.
Publicado: (2015)

Evaluation of aerosol IL-2 in sarcoma patients with lung metastases for future combination therapy with infused natural killer cells
por: Naing, Aung, et al.
Publicado: (2013)

Our experience of anti-interleukin 1 therapy
por: Gulez, N, et al.
Publicado: (2015)

In vivo synergy of radiation and hu14.18-IL2 immunocytokine results in a memory T cell response in a syngeneic murine melanoma model
por: Morris, Zachary S, et al.
Publicado: (2014)

P16-30. Induction of Tim-3 expression by the common gamma-chain cytokines IL-2, IL-7, IL-15 and IL-21
por: Jones, BR, et al.
Publicado: (2009)

Pathogenic roles of IL-6 and IL-6 blocking therapy on rheumatoid arthritis
por: Yoshizaki, K, et al.
Publicado: (2003)

TLR2/6 agonists and IFN-gamma treatment induces favorable immune cell recruiting signatures from melanoma associated with STAT1 and IL-32 signaling
por: Mauldin, Ileana S, et al.
Publicado: (2014)

The correlations of serum interleukin-6 (il-6) levels and serum soluble il-6 receptor levels with disease activity in systemic juvenile idiopathic arthritis patients with and without tocilizumab treatment
por: Lerkvaleekul, Butsabong, et al.
Publicado: (2014)

Selective costimulation by IL-15R/IL-15, but not IL-2R/IL-2, allows the induction of high numbers of tumor-specific CD8+ T cells by human dendritic cells matured in conditions of acute inflammation
por: Hansen, Morten, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8i5grs9b1u08ov7tdn2ere4214